Overview

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out what effects (good or bad) trabectedin (ET743) has on men with advanced prostate carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Dana-Farber Cancer Institute
PharmaMar
Treatments:
Trabectedin